Evidence map›Paper›PMID 37874503›Full record

ArticleIrish journal of medical science2024

YKL-40 in serum: a promising biomarker of juvenile SLE and strongly correlated with disease duration.

Asmaa A Ali, Rasha N Yousef, Mai S Elsheikh, Abeer R Salamah, Liang L Wu, Alshaimaa R Alnaggar, Noha M Khalil, Mervat E Behiry

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Irish journal of medical science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Asmaa A AliDepartment of Laboratory Medicine, School of Medicine, Jiangsu University, Zhenjiang, 212013, P. R., Zhenjiang, China.
Rasha N YousefDepartment of Clinical and Chemical Pathology, Medical Research and Clinical Studies Institute, National Research Center, Giza, Egypt. rashanazzih@yahoo.com.ORCID http://orcid.org/0000-0002-1694-4968
Mai S ElsheikhDepartment of Complementary Medicine, Medical Research and Clinical Studies Institute, National Research Center, Giza, Egypt.
Abeer R SalamahDepartment of Molecular Genetics and Enzymology, Human Genetics and Genomic Research Institute, National Research Center, Giza, Egypt.
Liang L WuDepartment of Laboratory Medicine, School of Medicine, Jiangsu University, Zhenjiang, 212013, P. R., Zhenjiang, China.
Alshaimaa R AlnaggarInternal Medicine Department, Rheumatology and Clinical Immunology Unit, KasrAlainy School of Medicine, Cairo University, Cairo, Egypt.
Noha M KhalilInternal Medicine Department, Rheumatology and Clinical Immunology Unit, KasrAlainy School of Medicine, Cairo University, Cairo, Egypt.
Mervat E BehiryInternal Medicine Department, Rheumatology and Clinical Immunology Unit, KasrAlainy School of Medicine, Cairo University, Cairo, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe biological function of YKL-40 is not well determined in different inflammatory and autoimmune diseases; however, some data highlighted its possible connection with disease activity.

aimWe investigated the diagnostic utility of serum YKL-40 in patients with SLE and examined its correlation with disease activity. Additionally, we examined any differences in serum YKL-40 levels between juvenile and adult SLE patients.

methodsWe included 78 female patients with SLE and 42 controls. The level of YKL-40 in serum was measured by ELISA.

resultsThe serum YKL-40 level in SLE patients was significantly higher compared to the control group (9 (3) ng/mL vs. 5.5 (0.1) ng/mL; p < 0.001). YKL-40 showed excellent diagnostic utility with an AUC of 1 (p < 0.001) and a cutoff point of 5.6, providing sensitivity and specificity of 100%. YKL-40 was higher in adolescents and those with a positive family history of SLE (p = 0.01 for both) and positively correlated with disease duration (r = 0.45, p < 0.001). YKL-40 level was significantly higher in patients with photosensitivity, fever, vasculitis, blood disorders, positive anti-dsDNA, and APL ab (p < 0.05 for all). Conversely, patients with skin manifestations had a significantly lower YKL-40 (p = 0.004). In juvenile SLE, the AUC was 0.65 and a p-value of 0.01, and at a cutoff value of (8.7) ng/mL, the sensitivity and specificity were 72% and 60%, respectively.

conclusionYKL-40 in serum could be a promising biomarker in patients with SLE, especially in adolescent-onset cases. It is independently influenced by disease duration, anemia, thrombocytopenia, positive anti-dsDNA, and APL ab features.

Indexed as

BiomarkersChitinase-3-Like Protein 1Lupus Erythematosus, SystemicAdolescentAdultCase-Control StudiesChildFemaleHumansYoung AdultBiomarkersCHI3L1 protein, humanChitinase-3-Like Protein 1Disease durationJuvenile onset SLESLEYKL-40

Identifiers

PMID37874503
PMCPMC11128401

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.